DARE BIOSCIENCE INC (DARE) Fundamental Analysis & Valuation

NASDAQ:DARE • US23666P2002

Current stock price

1.85 USD
0 (0%)
At close:
1.82 USD
-0.03 (-1.62%)
After Hours:

This DARE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. DARE Profitability Analysis

1.1 Basic Checks

  • In the past year DARE has reported negative net income.
  • In the past year DARE has reported a negative cash flow from operations.
  • DARE had negative earnings in each of the past 5 years.
  • In the past 5 years DARE reported 4 times negative operating cash flow.
DARE Yearly Net Income VS EBIT VS OCF VS FCFDARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

  • DARE's Return On Assets of -13.18% is fine compared to the rest of the industry. DARE outperforms 64.06% of its industry peers.
  • The Return On Equity of DARE (-141.84%) is worse than 69.27% of its industry peers.
Industry RankSector Rank
ROA -13.18%
ROE -141.84%
ROIC N/A
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DARE Yearly ROA, ROE, ROICDARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K -8K

1.3 Margins

  • DARE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DARE Yearly Profit, Operating, Gross MarginsDARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. DARE Health Analysis

2.1 Basic Checks

  • DARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • DARE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DARE Yearly Shares OutstandingDARE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
DARE Yearly Total Debt VS Total AssetsDARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • DARE has an Altman-Z score of -10.33. This is a bad value and indicates that DARE is not financially healthy and even has some risk of bankruptcy.
  • DARE's Altman-Z score of -10.33 is on the low side compared to the rest of the industry. DARE is outperformed by 72.40% of its industry peers.
  • DARE has a Debt/Equity ratio of 1.88. This is a high value indicating a heavy dependency on external financing.
  • DARE's Debt to Equity ratio of 1.88 is on the low side compared to the rest of the industry. DARE is outperformed by 77.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.88
Debt/FCF N/A
Altman-Z -10.33
ROIC/WACCN/A
WACC8.99%
DARE Yearly LT Debt VS Equity VS FCFDARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 1.18 indicates that DARE should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.18, DARE is doing worse than 79.69% of the companies in the same industry.
  • A Quick Ratio of 1.18 indicates that DARE should not have too much problems paying its short term obligations.
  • DARE has a worse Quick ratio (1.18) than 73.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.18
Quick Ratio 1.18
DARE Yearly Current Assets VS Current LiabilitesDARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. DARE Growth Analysis

3.1 Past

  • The earnings per share for DARE have decreased strongly by -140.38% in the last year.
EPS 1Y (TTM)-140.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1700%

3.2 Future

  • Based on estimates for the next years, DARE will show a very strong growth in Earnings Per Share. The EPS will grow by 60.10% on average per year.
  • The Revenue is expected to grow by 304.80% on average over the next years. This is a very strong growth
EPS Next Y71.44%
EPS Next 2Y65.61%
EPS Next 3Y74.81%
EPS Next 5Y60.1%
Revenue Next Year8700.33%
Revenue Next 2Y1213.09%
Revenue Next 3Y656.13%
Revenue Next 5Y304.8%

3.3 Evolution

DARE Yearly Revenue VS EstimatesDARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
DARE Yearly EPS VS EstimatesDARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

1

4. DARE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DARE. In the last year negative earnings were reported.
  • Also next year DARE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DARE Price Earnings VS Forward Price EarningsDARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DARE Per share dataDARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as DARE's earnings are expected to grow with 74.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.61%
EPS Next 3Y74.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DARE Dividend Analysis

5.1 Amount

  • No dividends for DARE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DARE Fundamentals: All Metrics, Ratios and Statistics

DARE BIOSCIENCE INC

NASDAQ:DARE (4/9/2026, 8:21:35 PM)

After market: 1.82 -0.03 (-1.62%)

1.85

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-26
Earnings (Next)05-11
Inst Owners8.53%
Inst Owner Change0%
Ins Owners0.71%
Ins Owner Change0%
Market Cap26.44M
Revenue(TTM)N/A
Net Income(TTM)-4.05M
Analysts82
Price Target10.97 (492.97%)
Short Float %1.64%
Short Ratio2.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.49%
Min EPS beat(2)23.04%
Max EPS beat(2)23.94%
EPS beat(4)3
Avg EPS beat(4)10.74%
Min EPS beat(4)-19.49%
Max EPS beat(4)23.94%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-95.4%
Min Revenue beat(2)-110.91%
Max Revenue beat(2)-79.89%
Revenue beat(4)0
Avg Revenue beat(4)-96.8%
Min Revenue beat(4)-110.91%
Max Revenue beat(4)-79.89%
Revenue beat(8)0
Avg Revenue beat(8)-85.89%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-19.04%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2697.6
P/FCF N/A
P/OCF N/A
P/B 9.25
P/tB 9.25
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0
BVpS0.2
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.18%
ROE -141.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.88
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 67.01%
Cap/Sales 7565.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.18
Quick Ratio 1.18
Altman-Z -10.33
F-Score3
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)1097.89%
Cap/Depr(5y)675.4%
Cap/Sales(3y)1956.65%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-140.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.92%
EPS Next Y71.44%
EPS Next 2Y65.61%
EPS Next 3Y74.81%
EPS Next 5Y60.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1700%
Revenue Next Year8700.33%
Revenue Next 2Y1213.09%
Revenue Next 3Y656.13%
Revenue Next 5Y304.8%
EBIT growth 1Y24.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y83.31%
OCF growth 3YN/A
OCF growth 5YN/A

DARE BIOSCIENCE INC / DARE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for DARE BIOSCIENCE INC?

ChartMill assigns a fundamental rating of 1 / 10 to DARE.


Can you provide the valuation status for DARE BIOSCIENCE INC?

ChartMill assigns a valuation rating of 1 / 10 to DARE BIOSCIENCE INC (DARE). This can be considered as Overvalued.


What is the profitability of DARE stock?

DARE BIOSCIENCE INC (DARE) has a profitability rating of 1 / 10.


What is the financial health of DARE BIOSCIENCE INC (DARE) stock?

The financial health rating of DARE BIOSCIENCE INC (DARE) is 1 / 10.


Can you provide the expected EPS growth for DARE stock?

The Earnings per Share (EPS) of DARE BIOSCIENCE INC (DARE) is expected to grow by 71.44% in the next year.